Corona Remedy Files Papers with Sebi Rs 800 crore.

New Delhi, Market Regulator Sebi on Wednesday paid Rs. He sought his approval to float the initial public offering fur (IPO) of Rs 800 crore. According to the Red Harring Prospectus (DRHP) draft, IPO is full sales (OFS) by promoters and existing investors.

Plan to flaw the stock under existing investors -Sapia Investments, Anchor Partners and Sage Investment Trust -OFS Route. Since it is an OFS, the company will not receive any income from public issues.

Corona Remedy is a pharmaceutical formulation company that developed, developed in women’s healthcare, cardio-diabetes, pain management, urology and other therapeutic sectors, in production and marketing products.

Its diverse product portfolio includes 67 brands of therapeutic sectors such as women’s healthcare, cardio-diabatoes, pain management and urology, among others, by December 31, 2024.

JM Financial, IIFL Capital Services and Kotak Mahindra Capital Company are lead managers running the book on this issue.